Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Adocia currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio involves 1 distinct examiner and a single distinct art unit, reflecting a highly focused point of contact at the patent office. This concentration suggests that the pending matter falls within a specific technical niche handled by a specialized group.
MIKNIS, ZACHARY J is the busiest examiner for the company, managing the current workload. This represents the entirety of the current pending workload for the portfolio. For the practitioner, this means that the immediate success of the company's prosecution efforts depends on the review of this specific individual. The presence of a single pending office action indicates a limited current engagement with the patent office compared to larger portfolios. All prosecution strategy is currently directed toward this sole interaction, emphasizing the importance of the relationship with the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18370720 | COMPOSITIONS COMPRISING AT LEAST AN INSULIN AND AN AMYLIN RECEPTOR AGONIST FOR TREATING DIABETES, IN A PATIENT/PERSON HAVING A BMI OF MORE THAN 28 KG/M² AND/OR AN HBA1C OF MORE THAN 7.6% | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18370720 | COMPOSITIONS COMPRISING AT LEAST AN INSULIN AND AN AMYLIN RECEPTOR AGONIST FOR TREATING DIABETES, IN A PATIENT/PERSON HAVING A BMI OF MORE THAN 28 KG/M² AND/OR AN HBA1C OF MORE THAN 7.6% | MIKNIS, ZACHARY J | 1658 | §103 | Non-Final OA | — | Pending | Sep 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdocia has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zachary J Miknis has the most, with 1 of Adocia's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
